Incentives in Diabetic Eye Assessment by Screening (IDEAS) trial: a three-armed randomised controlled trial of financial incentives

Gaby Judah,1 Ara Darzi,1 Ivo Vlaev,2 Laura Gunn,3 Derek King,4 Dominic King,1 Jonathan Valabhji,5 Lisa Bishop,6 Adrian Brown,7 Grant Duncan,6 Anna Fogg,6 Gemma Harris,7 Peter Tyacke6 and Colin Bicknell1*

1Department of Surgery and Cancer, Imperial College London, London, UK
2Warwick Business School, University of Warwick, Coventry, UK
3Public Health Program, Stetson University, DeLand, FL, USA
4Personal Social Services Research Unit, London School of Economics and Political Science, London, UK
5Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK
61st Retinal Screen Ltd, Sandbach, UK
7Public Health England, London, UK

*Corresponding author

Declared competing interests of authors: Colin Bicknell has received unrelated fees for consultancy and speaker honoraria from Hansen Medical, Medtronic and Bolton Medical, during the conduct of the study.

Published March 2017
DOI: 10.3310/hsdr05150

Scientific summary

Incentives in Diabetic Eye Assessment by Screening Trial (IDEAS)
Health Services and Delivery Research 2017; Vol. 5: No. 15
DOI: 10.3310/hsdr05150

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Diabetes is estimated to currently affect > 8% of the global population. Treating diabetes and its complications is estimated to cost 10% of the NHS budget. This is primarily due to the major complications of neuropathy, nephropathy and retinopathy, as well as complications of ischaemic heart disease, stroke and limb loss, as diabetes is a major risk factor for the generation and progression of atherosclerosis.

One of the microvascular complications of diabetes is diabetic retinopathy, which can affect patients with type 1 and type 2 diabetes. This complication is characterised by the growth of new, fragile blood vessels in the eye, which cause significant retinal damage from microhaemorrhage, leading to sight loss. In England, every year there are 1280 new cases of blindness from diabetic retinopathy, which is one of the leading causes of blindness in the working-age population in England. Early diagnosis and treatment of retinopathy significantly reduces the risk of blindness. Therefore, everyone in England with diabetes (aged ≥ 12 years) is offered annual diabetic retinopathy screening by the diabetic eye screening (DES) programme. The rate of screening uptake is 81%, leaving many people at risk of avoidable sight loss. Furthermore, screening rates are lower in more socially deprived areas. Therefore, simple, cost-effective strategies are needed to achieve the full benefits of screening, and to do so in an equitable way.

There is increasing interest in using financial incentives to encourage healthy behaviours. Evidence suggests that incentives may be more effective at promoting infrequent behaviours (e.g. vaccinations) than frequently performed behaviours (e.g. smoking). Therefore, incentives could be expected to be an effective strategy to promote screening uptake. The impact of financial incentives in screening is variable, and has not previously been investigated in a randomised trial of DES uptake.

Financial incentives are sometimes thought of as controversial, as they could be seen as a form of coercion. However, appropriate incentives could reduce inequalities in health outcomes. Furthermore, incentives may be seen as a way to help people to align their behaviour with their underlying intentions, and therefore enhance rather than reduce behavioural autonomy. Incentives could be better perceived as acceptable if they are effective and cost-effective, and if they benefit participants and wider society.

The design of financial incentive schemes impacts on their effectiveness. The field of behavioural economics provides robust psychological phenomena, which explain and predict behaviour. One principle considered in the design of the incentives for this study was ‘reference points’, which indicates that small incentives can have an impact on behaviour, but there is little additional advantage to increasing the level of incentive. Therefore, one incentive in this study was selected to be £10 to cover time or travel costs of the patient.

The second key principle used to inform the design of the trial incentives was the ‘overweighting of small probabilities’, whereby people are likely to overvalue small probabilities. This explains the popularity of lotteries and insurance. The use of lotteries in incentive schemes can be a more effective way of using limited resources than smaller individual rewards. Work conducted by the trial team prior to this study final design determined that people might be categorised as risk avoiders or risk seekers (favouring the riskiest option with the highest potential payoff). Therefore, a lottery incentive was selected to represent the highest level of incentive that could be provided by the trial funding, which would represent the same average payoff as the fixed incentive. This was a 1 in 100 probability of winning £1000.
Objectives

To test whether or not financial incentives are an effective strategy to encourage participation in the screening programme. Secondarily to understand if the design of the financial incentive scheme used affects its effectiveness in influencing participation in health screening uptake or attracts patients who have a different demographic or sociodemographic status to those who attend screening regularly. If financial incentives were found to improve attendance, then a final objective was to test if these could be cost-effective if rolled out on a population-wide basis.

Methods

Participants

Eligible participants were identified by the screening provider, 1st Retinal Screen Ltd, prior to the start of the study. To be eligible, participants had to be in the geographical area due to be invited for screening (defined as the patient’s general practitioner being within Kensington, Chelsea or Westminster). Participants also had to be aged \( \geq \) 16 years, and to have failed to attend screening for at least two annual appointments, or to have failed to contact the screening service to try to rearrange their appointment.

As the usual invitation process continued for patients in the trial, a minimum 2-month window was left between any contact as part of usual care, and invitation into the trial, in order to avoid contacting participants who were late to contact the screening service but who still intended to do so. In order to ensure that the contact details were correct, participants were excluded if a post-office return had been received from their address. Participants were selected based on these criteria using an electronic search of the screening provider database. In order to further verify that correct details were used, and that only eligible patients were contacted, the study population was checked against the patient register immediately prior to invitation to the trial.

Design and procedure

The study was a three-arm randomised controlled trial. The impact of two different types of financial incentives was compared with a control group, who were sent the usual appointment invitation letter. Participants were randomised at the start of the study by the statistician to the three arms according to a 1.4 : 1 : 1 randomisation ratio, in order to achieve maximum statistical efficiency. Appointment invitation letters were sent to participants 4 weeks prior to a planned trial appointment date.

The study took place at a diabetic retinopathy screening clinic within St Mary’s Hospital, London, which is part of Imperial College Healthcare NHS Trust. Dedicated clinics were held for each of the three conditions, in order to avoid patients becoming aware of incentives being offered in the different trial conditions. Participants could rearrange their appointment once if necessary, and still be eligible for the incentive.

Conditions

Control

This group received the usual appointment invitation letter, inviting patients to a fixed appointment at a particular date and time.

Fixed incentive

This group were sent the usual invitation letter, including a voucher for £10 if they attend their appointment. The fixed incentive was paid in cash by the researcher at the screening clinic.

Lottery incentive

This group were sent the usual invitation letter, which included a voucher for a 1 in 100 chance of winning £1000 if they attended their appointment. The lottery was conducted following each lottery clinic using a computer program, which gave each attending participant a 1 in 100 probability of being selected as a winner. If no winners were selected in this way, one winner was planned to be selected at random at the end of the study, from all attenders from the lottery group.
Measures
Following completion of the study, the data set was generated by the data manager at 1st Retinal Screen Ltd, using a database search of their system to extract all relevant attendance and demographic data.

The primary end point of the study was the proportion of invitees who attended screening. Demographic information was collected for all invited participants on gender, age, deprivation (measured using the Index of Multiple Deprivation score), years registered and distance from home to the screening centre. If participants were excluded from the trial after randomisation, but before being invited, the reason for this was recorded. These reasons were categorised in the final data set to facilitate comparisons. For those participants who attended their screening appointment, data on their screening outcome score were collected, and aggregated by intervention group. When patients attended their appointments, the screener asked them for any reasons for non-attendance at their past few appointments, in order to see if there were differences between the intervention groups, and to explore common barriers to attendance in this hard-to-reach group.

Demographic details were also collected for the patient population who were not invited to the trial, in order to compare the Incentives in Diabetic Eye Assessment by Screening Trial population with the remainder of the retinopathy screening cohort. This non-trial population were categorised whether or not they are regular attenders at screening (defined as having attended at least twice in the past 3 years).

Analysis plan
The primary outcome was the attendance rate by treatment group, compared using chi-squared tests. Risk differences and risk ratios are presented to assess whether or not any significant differences between groups exist.

Further exploratory subgroup analyses were conducted to explore the third research question about whether or not the incentive schemes attract patients with a different socioeconomic or demographic status. Comparisons were made to those who are classified as regular ‘current’ attenders to assess possible differences through demographic covariates between regular attenders and non-attenders.

A pre-planned cost-effectiveness analysis would determine whether or not the intervention was a cost-effective way to increase screening.

Results
Of the 1274 patients who were deemed eligible and randomised, 223 became ineligible before being sent the invitation letter. (The most common reason for this was attending their screening appointment prior to the trial.) This left 1051 invited participants, 435 in the control group, and 312 and 304 in the fixed and lottery groups, respectively. There were no significant differences between groups in terms of age, gender, deprivation score, distance from clinic or years registered.

A smaller proportion of trial patients than regular attenders from the general screening population were above the age of 65 years; however, a larger proportion than non-regular attenders from the general population were older than 65 years.

Considering the primary outcome, 7.8% control participants, 5.5% from the fixed group and 3.3% from the lottery group attended screening. Those in an incentive group were 44% less likely to attend screening than controls [relative risk (RR) 0.56, 95% confidence interval (CI) 0.34 to 0.92].

Examining differences between incentive groups showed that those in the lottery group were 58% less likely to attend screening than controls (RR 0.42, 95% CI 0.18 to 0.98). No significant differences in attendance were found between fixed incentive and control groups (RR 0.70, 95% CI 0.35 to 1.39), or fixed incentive and lottery incentive groups (RR 1.66, 95% CI 0.65 to 4.21).
There were no significant differences in sociodemographic variables between attenders and non-attenders. There were no significant differences between attenders in the control or incentive conditions.

Of the 60 participants who attended their trial appointment, 78% did not require any additional management aside from annual recall to screening (82% from the control group and 73% from the incentive groups). Chi-squared analysis ($p = 0.387$) along with pairwise comparisons verified that there were no significant differences in whether or not additional management was recommended between the different randomised groups.

Reasons for past non-attendance were split into three categories: organisational problems, practical/logistical problems, and not thinking that they needed to be screened. A chi-squared analysis revealed no significant association between reason for non-attendance and belonging to the control group compared with the incentive groups ($p = 0.119$). Half the participants who should have attended screening in the past stated they did not attend past appointments because of organisational reasons, whereas one-quarter each selected practical/logistic problems and that they did not think they needed to attend.

A sensitivity analysis was performed, which excluded any participants who had a reason for ineligibility following the invitation letter being sent. Similar results were obtained showing that the incentive group were 52% less likely to attend screening than controls (RR 0.48, 95% CI 0.29 to 0.80). Those in the lottery group were 58% less likely to attend screening than controls (RR 0.42, 95% CI 0.18 to 0.97). Again, no significant differences in attendance were found between fixed incentive compared with control (RR 0.54, 95% CI 0.25 to 1.16), or fixed incentive compared with lottery incentive (RR 1.30, 95% CI 0.49 to 3.49).

A second sensitivity analysis included as attenders participants who needed to arrange their trial appointment but were booked onto normal screening as they could not attend on another trial clinic day. This analysis showed a significant, but weak, difference in attendance between the incentive group and controls (RR 0.63, 95% CI 0.40 to 0.99); there was no significant difference in comparisons between any other groups.

**Conclusions**

The numbers attending retinopathy screening were low, with attendance rates of 7.8% in the control group, 5.5% in the fixed incentive group (£10) and 3.3% in the lottery incentive group. Unexpectedly, the incentive groups combined were less likely to attend screening than those who received a standard appointment invitation. Considering each incentive scheme separately, those in the lottery group were less likely to attend than those in the control group (there was no significant differences between the control and fixed incentive group). Incentives were therefore not effective or cost-effective at improving screening uptake in poor attenders at DES.

The sociodemographic characteristics (age, gender, deprivation, distance from screening centre and years registered) of attenders were not different from those not attending. There were also no sociodemographic differences between attenders from the control and incentive groups.

One explanation for the observed negative effect may be that being offered an incentive for a health check may elicit feelings of dread, through making people think the appointment must be unpleasant if they are being paid to attend. This could make them less likely to attend. The fact that the lottery, which offered a high-value incentive, had significantly worse attendance rates supports this theory, as the larger incentive may have promoted greater feelings on dread than the more modest £10 incentive offer.

The results were unexpected, as negative effects of incentives are uncommon, and on the whole, incentives have been found to be effective at promoting screening. However, a previous cohort study observed that offering financial incentives for diabetic retinopathy screening was associated with significantly lower attendance rates. This therefore supports the present findings that financial incentives may be detrimental in promoting diabetic retinopathy screening.
The results indicate the importance of testing interventions in context even if they are supported by theory, or appear to be effective in other contexts. (For example, incentives may have a different effect in the USA from that in the UK, as people in the USA are more accustomed to financial transactions in health care.)

As financial incentives do not appear to be a promising avenue to explore for promoting diabetic retinopathy screening, future research should focus on investigating barriers to adherence, and other methods for effectively overcoming these in order to promote greater attendance.

**Trial registration**

This trial is registered as ISRCTN14896403.

**Funding**

Funding for this study was provided by the Health Services and Delivery Research programme of the National Institute for Health Research.
Criteria for inclusion in the Health Services and Delivery Research journal

Reports are published in Health Services and Delivery Research (HS&DR) if (1) they have resulted from work for the HS&DR programme or programmes which preceded the HS&DR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

HS&DR programme
The Health Services and Delivery Research (HS&DR) programme, part of the National Institute for Health Research (NIHR), was established to fund a broad range of research. It combines the strengths and contributions of two previous NIHR research programmes: the Health Services Research (HSR) programme and the Service Delivery and Organisation (SDO) programme, which were merged in January 2012.

The HS&DR programme aims to produce rigorous and relevant evidence on the quality, access and organisation of health services including costs and outcomes, as well as research on implementation. The programme will enhance the strategic focus on research that matters to the NHS and is keen to support ambitious evaluative research to improve health services.

For more information about the HS&DR programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hsdr

This report
The research reported in this issue of the journal was funded by the HS&DR programme or one of its preceding programmes as project number 12/64/112. The contractual start date was in July 2014. The final report began editorial review in July 2016 and was accepted for publication in December 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HS&DR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HS&DR programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HS&DR programme or the Department of Health.
Health Services and Delivery Research Editor-in-Chief

Professor Jo Rycroft-Malone  Professor of Health Services and Implementation Research, Bangor University, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk